Molly Gallagher

Dr. Molly Gallagher


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2018 in Viruses
Verified
Journal Article
Open access
PDF file
MGMolly Gallagher
Molly Gallagher
CBChristopher Byron Brooke
Christopher Byron Brooke
RKRuian Ke
Ruian Ke
KKKatia Koelle
Katia Koelle
The spread of viral pathogens both between and within hosts is inherently a spatial process. While the spatial aspects of viral spread at the epidemiological level have been increasingly well characterized, the spatial aspects of viral spread within infected hosts are still understudied. Here, with a focus on influenza A viruses (IAVs), we first review experimental studies that have shed light on the mechanisms and spatial dynamics of viral spread within hosts. These studies provide strong empirical evidence for highly localized IAV spread within hosts. Since mathematical and computational within-host models have been increasingly used to gain a quantitative understanding of observed viral dynamic patterns, we then review the (relatively few) computational modeling studies that have shed light on possible factors that structure the dynamics of spatial within-host IAV spread. These factors include the dispersal distance of virions, the localization of the immune response, and heterogeneity in host cell phenotypes across the respiratory tract. While informative, we find in these studies a striking absence of theoretical expectations of how spatial dynamics may impact the dynamics of viral populations. To mitigate this, we turn to the extensive ecological and evolutionary literature on range expansions to provide informed theoretical expectations. We find that factors such as the type of density dependence, the frequency of long-distance dispersal, specific life history characteristics, and the extent of spatial heterogeneity are critical factors affecting the speed of population spread and the genetic composition of spatially expanding populations. For each factor that we identified in the theoretical literature, we draw parallels to its analog in viral populations. We end by discussing current knowledge gaps related to the spatial component of within-host IAV spread and the potential for within-host spatial considerations to inform the development of disease control strategies.

23 November 2020 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
MGMolly Gallagher
Molly Gallagher
ASAndrew J. Sieben
Andrew J. Sieben
KNKristin N. Nelson
Kristin N. Nelson
AKAlicia N. M. Kraay
Alicia N. M. Kraay
WOWalter A. Orenstein
Walter A. Orenstein
KKKatia Koelle
Katia Koelle

11 August 2020 in medRxiv
Verified
Preprint
Open access
PDF file
MGMolly Gallagher
Molly Gallagher
ASAndrew J. Sieben
Andrew J. Sieben
KNKristin N. Nelson
Kristin N. Nelson
Alicia KraayAlicia Kraay
Alicia Kraay
BLBen Lopman
Ben Lopman
KKKatia Koelle
Katia Koelle
Significant progress has already been made in development and testing of SARS-CoV-2 vaccines, and Phase III clinical trials have begun for 6 novel vaccine candidates to date. These Phase III trials seek to demonstrate direct benefits of a vaccine on vaccine recipients. However, vaccination is also known to bring about indirect benefits to a population through the reduction of virus circulation. The indirect effects of SARS-CoV-2 vaccination can play a key role in reducing case counts and COVID-19 deaths. To illustrate this point, we show through simulation that a vaccine with strong indirect effects has the potential to reduce SARS-CoV-2 circulation and COVID-19 deaths to a greater extent than an alternative vaccine with stronger direct effects but weaker indirect effects. Protection via indirect effects may be of particular importance in the context of this virus, because elderly individuals are at an elevated risk of death but are also less likely to be directly protected by vaccination due to immune senescence. We therefore encourage ongoing data collection and model development aimed at evaluating the indirect effects of forthcoming SARS-CoV-2 vaccines.

13 March 2021 in medRxiv
Verified
Preprint
Open access
PDF file
Alicia KraayAlicia Kraay
Alicia Kraay
MGMolly Gallagher
Molly Gallagher
YGYang Ge
Yang Ge
PHPeichun Han
Peichun Han
JBJulia M. Baker
Julia M. Baker
BLBenjamin A Lopman
Benjamin A Lopman
In response to the COVID-19 pandemic, widespread non-pharmaceutical interventions (NPIs), including physical distancing, mask wearing, and enhanced hygiene, have been implemented. As of March 2021, three effective vaccines have been approved for emergency use in the United States, with several other vaccines in the pipeline. We use a transmission model to study when and how NPIs could be relaxed in the United States with relative safety as vaccination becomes more widespread. We compare different relaxation scenarios where NPIs begin to relax 0-9 months after vaccination begins for both a one dose and two dose strategy, with historical levels of social interactions being reached within 1 month to 1 year. In our model, vaccination can allow widespread relaxation of NPIs to begin safely within 2 to 9 months, greatly reducing deaths and peak health system burden compared to relaxing NPIs without vaccination. Vaccinated individuals can safely begin to relax NPIs sooner than unvaccinated individuals. The extent of delay needed to safely reopen depends primarily on the rate of vaccine rollout, with the degree of protection against asymptomatic infection playing a secondary role. If a vaccination rate of 3 million doses/day can be achieved, similar to the typical rollout speed of seasonal influenza vaccination, NPIs could begin to be safely relaxed in 2-3 months. With a vaccination rate of 1 million doses/day, a 6–9-month delay is needed. A one dose strategy is preferred if relative efficacy is similar to a two-dose series, but the relative benefit of this strategy is minimal when vaccine rollout is fast. Due to the urgent need to pursue strategies that enable safe relaxation of NPIs, we recommend a two-dose strategy with an initial delay of at least 3 months in relaxing restrictions further, and that the speed of vaccine rollout be given immediate priority.

4 November 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
VNVijay Narayan
Vijay Narayan
BMBrian Merritt
Brian Merritt
SCSanjeevani Choudhery
Sanjeevani Choudhery
DJDaniel Jimenez
Daniel Jimenez
STStanley Ta
Stanley Ta
MGMolly Gallagher
Molly Gallagher
Accurate and reproducible metagenomic analysis is essential for effective infectious disease surveillance. Targeted diagnostics such as culturing, antigen assays, and multiplex PCR panels identify only predefined organisms and can fail to identify atypical or novel infections. Shotgun metagenomics offers hypothesis-free detection, but adoption is limited by workflow complexity, dependence on mutable reference databases, and high computational cost. To combat these challenges, we introduce MicrobeRT, an integrated suite of genomic language models fine-tuned to classify metagenomic sequencing reads across three tasks: (i) species level taxonomic identification, (ii) antibiotic resistance gene detection, and (iii) pathogenicity assessment. The framework builds on three pre-trained genomic language models - Nucleotide Transformer (Dalla-Torre et al 2025), DNABERT (Ji et al 2021, Zhou et al 2024), and HyenaDNA (Nguyen et al 2024) - leveraging their large-scale genomic pre-training, adaptability to downstream tasks, and, in the case of HyenaDNA, ability to capture long-range sequence dependencies. The models are fine-tuned on large, curated datasets spanning microbial, viral, fungal, and human genomes, including more than 500,000 genomes and 250,000 antibiotic resistance gene sequences. To evaluate the performance of our fine-tuned genomic language models across classification tasks, we developed a benchmarking framework that compares MicrobeRT against state-of-the-art (SOTA) bioinformatics tools. Across both simulated and empirical datasets, the models achieve strong performance while reducing computational overhead. MicrobeRT is released as open-source software, enabling further fine-tuning and reproducible integration of alternative models and classifiers. We also demonstrate seamless, drop-in integration by incorporating our fine-tuned taxonomic classification models as an optional add-on within the open-source TaxTriage pipeline (Merritt et al 2026). MicrobeRT demonstrates the feasibility of three clinically relevant multi-label analyses, offering a practical path to scalable, reproducible metagenomic diagnostics and enabling broader deployment of AI/ML-enhanced infectious disease testing.

22 May 2026 in bioRxiv
Verified
Preprint
Open access
PDPedro C Dal-Castel
Pedro C Dal-Castel
JRJessica Resnick
Jessica Resnick
JSJames P Sluka
James P Sluka
MGMolly Gallagher
Molly Gallagher
MHMika Helfers
Mika Helfers
JGJames A Glazier
James A Glazier
In the respiratory epithelium, interferon (IFN)-induced antiviral resistance acts as a defense against infection. Influenza A viruses (IAVs) have evolved multiple strategies to counteract these defenses, including expression of the viral protein NS1, which inhibits both IFN production and the IFN-mediated transcription of Interferon Stimulated Genes (ISG) in infected cells. However, experiments show that this inhibition is imperfect, especially at a low multiplicity of infection (MOI). One hypothesis to describe this phenomenon relies on the presence of Semi-infectious Particles (SIPs) that fail to express NS1. In this scenario, the IFN response is incompletely suppressed at low MOI, while it is successfully inhibited at high MOI because most cells are infected by multiple virions, allowing complementation to rescue NS1 expression. To test this hypothesis, we developed a computer simulation that models viral gene defects and complementation. We compared the model outputs with in vitro experiments at different MOIs. To assess inter-host reproducibility and calibrate the model parameters, we measured IFN levels and viral load over time in bronchial epithelial cell cultures from five human donors. We observed no statistically significant heterogeneity in IFN response or virus production between donors, and the calibrated simulation fits the experimental time series for IFN and viral load. Consistent with literature (1,2), the model predicted higher IFN levels at low MOI than at high MOI. Finally, simulations of IFN treatment applied before and during infection showed reduced viral load, in agreement with our experiments. Increasing the viral genome defect rate above the experimentally estimated rate increased IFN levels and reduced viral load. High MOI simulations showed lower cumulative IFN levels, while NS1 knockout recovered high IFN levels. These results demonstrate the ability of mechanistic models of viral dynamics to predict the innate immune response of epithelial cells during viral infection.